Breaking News Instant updates and real-time market news.

CTSO

CytoSorbents

$9.05

-0.5 (-5.24%)

, KZR

Kezar Life Sciences

$25.47

-0.75 (-2.86%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55

Jefferies to hold a conference

London Healthcare Conference will be held in London, England on November 14-15.

CTSO

CytoSorbents

$9.05

-0.5 (-5.24%)

KZR

Kezar Life Sciences

$25.47

-0.75 (-2.86%)

NERV

Minerva

$8.29

0.15 (1.84%)

CNMD

Conmed

$68.14

-0.1 (-0.15%)

KDMN

Kadmon

$2.46

-0.07 (-2.77%)

SLGL

Sol-Gel Technologies

$6.90

-0.2 (-2.82%)

JAZZ

Jazz Pharmaceuticals

$141.65

-9.05 (-6.01%)

LNTH

Lantheus

$15.70

0.35 (2.28%)

AUPH

Aurinia Pharmaceuticals

$5.17

-0.05 (-0.96%)

CRBP

Corbus Pharmaceuticals

$5.87

-0.49 (-7.70%)

CNCE

Concert Pharmaceuticals

$11.29

-0.505 (-4.28%)

SGMO

Sangamo

$9.50

-1.3 (-12.04%)

CNST

Constellation Pharmaceuticals

$5.83

0.025 (0.43%)

CTLT

Catalent

$37.90

-0.34 (-0.89%)

URGN

UroGen Pharma

$47.81

1.48 (3.19%)

ARRY

Acquired by PFE

$14.53

-0.18 (-1.22%)

WST

West Pharmaceutical

$106.46

-0.37 (-0.35%)

RUBY

Rubius Therapeutics

$18.47

0.71 (4.00%)

CARA

Cara Therapeutics

$18.12

-0.8 (-4.23%)

  • 15

    Nov

  • 27

    Nov

  • 27

    Nov

  • 01

    Dec

  • 03

    Dec

  • 20

    Dec

CTSO CytoSorbents
$9.05

-0.5 (-5.24%)

KZR Kezar Life Sciences
$25.47

-0.75 (-2.86%)

07/16/18
JEFF
07/16/18
INITIATION
Target $23
JEFF
Buy
Jefferies starts Kezar Life Sciences with Buy rating, $23 target
Jefferies analyst Maury Raycroft initiated coverage of Kezar Life Sciences with a Buy rating and $23 price target. The company offers a straightforward story as KZR-616 is "de-risked," best-in-class and offers an "appealing market opportunity."
07/16/18
JEFF
07/16/18
INITIATION
Target $23
JEFF
Buy
Kezar Life Sciences initiated with a Buy at Jefferies
Jefferies started Kezar Life Sciences with a Buy rating and $23 price target.
07/16/18
COWN
07/16/18
INITIATION
COWN
Outperform
Kezar Life Sciences initiated with an Outperform at Cowen
Cowen analyst Phil Nadeau initiated Kezar Life Sciences with an Outperform rating as he expects the generation of shareholder value as its development progresses with its lupus drug candidate, KZR-616.
07/16/18
WELS
07/16/18
INITIATION
Target $30
WELS
Outperform
Kezar Life Sciences initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Kezar Life Sciences with an Outperform rating and $30 price target based on what he views as a highly leverageable platform and pipeline of novel immunoproteasome inhibitors for autoimmune disease, substantial validation from less selective approved proteasome inhibitors for cancer, proximity to proof-of-concept data in Systemic Lupus and Lupus Nephritis, and prospects for rapid expansion to other autoimmune diseases, including several that could support breakthrough designation and accelerated approval path.
NERV Minerva
$8.29

0.15 (1.84%)

08/03/18
SBSH
08/03/18
NO CHANGE
Target $19
SBSH
Buy
Minerva price target raised to $19 from $11 at Citi
Citi analyst Joel Beatty raised his price target for Minerva Neurosciences to $19 saying the company is an "overlooked" SMID-cap biotech with a differentiated Phase 3 schizophrenia drug. The analyst believes the Phase 3 trial of lead agent Roluperidone is likely to be successful when results read out in the first half of 2019. Negative symptoms of schizophrenia is a large market opportunity for which Roluperidone appears to have a lead of at least a couple of years toward being first to market, Beatty tells investors in a post-earnings research note. Further, he believes the company has an attractive pipeline of three other neurology agents beyond Roluperidone. His new price target reflects an increase in the probability of success of Roluperidone in Phase 3 to 65% from 50%.
CNMD Conmed
$68.14

-0.1 (-0.15%)

08/30/18
LEER
08/30/18
NO CHANGE
Target $81
LEER
Market Perform
CONMED price target raised to $81 from $76 at Leerink
Leerink analyst Richard Newitter raised his price target for CONMED to $81 from $76 to reflect recent multiple expansion for the group. The analyst reiterates a Market Perform rating on the shares.
10/15/18
LEHM
10/15/18
INITIATION
LEHM
Equal Weight
CONMED initiated with an Equal Weight at Barclays
Barclays analyst Kristen Stewart initiated CONMED with an Equal Weight rating and $78 price target.
08/02/18
NEED
08/02/18
NO CHANGE
Target $83
NEED
Buy
CONMED price target raised to $83 from $73 at Needham
Needham analyst Mike Matson raised his price target on Conmed to $83 and kept his Buy rating after its Q2 revenue and earnings beat. The analyst notes the company's 7.4% increase in constant-currency revenue growth, 190bp gross margin expansion, and the resulting increases in SG&A and R&D spending. Matson expects Conmed to sustain its revenue growth of over 6% while exceeding consensus estimates.
06/25/18
PIPR
06/25/18
NO CHANGE
Target $61
PIPR
Neutral
Stryker acquisition of SafeAir may pose thread to CONMED, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says that today's announcement of Stryker (SYK) acquiring SafeAir marks the second time that the company tried to enter the surgical smoke evacuation market, which it likely views as an "appealing" market. The analyst notes that the deal could eventually result in a product that could pose a competitive threat to CONMED (CNMD), though he also thinks that it should take Stryker some time to refine the SafeAir products and properly commercialize them. O'Brien keeps his Neutral rating and $61 price target on CONMED.
KDMN Kadmon
$2.46

-0.07 (-2.77%)

10/17/18
WBBS
10/17/18
UPGRADE
WBBS
Hold
Kadmon upgraded to Hold from Sell at WBB Securities
02/13/18
JEFF
02/13/18
NO CHANGE
Target $16
JEFF
Buy
Kadmon price target raised to $16 from $9 at Jefferies
Jefferies analyst Biren Amin raised his price target for Kadmon Holdings to $16 after the company announced positive data on its Phase II trial of KD025 in idiopathic pulmonary fibrosis. The absolute improvement of 127 mL between arms surpasses the bar of 45-85 mL seen with existing therapies and the shares should react positively, Amin tells investors in a research note. He keeps a Buy rating on Kadmon shares.
02/13/18
PIPR
02/13/18
NO CHANGE
Target $9
PIPR
Overweight
Kadmon price target raised to $9 after data on KD025 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff noted that Kadmon announced "positive" topline Phase 2 data on KD025 in 29 evaluable idiopathic pulmonary fibrosis, or IPF, patients. Upon adding value for KD025 in IPF, the analyst increased his price target on Kadmon shares to $9 from $7 and reiterated his Overweight rating on the stock.
12/21/17
JEFF
12/21/17
NO CHANGE
Target $9
JEFF
Buy
Kadmon Q1 data could bring 'significant' upside, says Jefferies
Jefferies analyst Biren Amin believes Kadmon's Phase II data for KD025 in chronic graft-versus-host disease, expected in Q1 of 2018, represent "significant" upside with little downside risk. KD025 has shown "encouraging activity" in a difficult to treat population, Amin tells investors in a research note. He assumes U.S. market entry of KD025 for treatment of chronic graft-versus-host disease in 2020 and estimates U.S. peak sales of 333.1M. The analyst has a Buy rating on Kadmon shares with a $9 price target.
SLGL Sol-Gel Technologies
$6.90

-0.2 (-2.82%)

07/16/18
HCWC
07/16/18
INITIATION
Target $21
HCWC
Buy
Sol-Gel Technologies initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Sol-Gel Technologies with a Buy rating and $21 price target. The analyst believes peak Twin sales may approach $260M by 2028 while while Vered might reach peak sales of $785M in 2027.
02/26/18
JMPS
02/26/18
INITIATION
Target $20
JMPS
Outperform
Sol-Gel Technologies initiated with an Outperform at JMP Securities
JMP Securities analyst Donald Ellis started Sol-Gel Technologies with an Outperform rating and $20 price target, stating that dermatologists prefer topical formulations, like the ones the company is developing, for treating most patients. Ellis added that Sol-Gel TWIN program showed "very impressive" Phase 2 results in acne treatment.
02/26/18
BMOC
02/26/18
INITIATION
Target $18
BMOC
Outperform
Sol-Gel Technologies initiated with an Outperform at BMO Capital
BMO Capital analyst Gary Nachman initiated Sol-Gel Technologies with an Outperform rating and a price target of $18. Nachman contends that the company's proprietary topical formulation technology is the basis for a robust late-stage pipeline in acne and rosacea - "significant markets in dermatology", adding that the products TWIN for acne and VERED for rosacea have de-risked the stock with strong Phase 2 data and very positive physician feedback. The analyst adds that Sol-Gel Technologies trades at a compelling valuation and may also become a target in an M&A deal.
02/26/18
02/26/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Walmart (WMT) initiated with a Neutral and Target (TGT) initiated with an Outperform at Credit Suisse. 2. Hudson (HUD) initiated with a Buy at Goldman Sachs, a Buy at UBS, an Equal Weight at Morgan Stanley and an Outperform at Credit Suisse. 3. VICI Properties (VICI) initiated with a Buy at Stifel, a Neutral at Goldman Sachs and an Equal Weight at Barclays. 4. Sage Therapeutics (SAGE) initiated with an Overweight at Morgan Stanley. 5. Sol-Gel Technologies (SLGL) initiated with a Buy at Jefferies and an Outperform at BMO Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
JAZZ Jazz Pharmaceuticals
$141.65

-9.05 (-6.01%)

10/19/18
PIPR
10/19/18
NO CHANGE
Target $213
PIPR
Overweight
Jazz shares could rally over $250 with JZP-258 success, says Piper Jaffray
After taking a closer look at the potential impact of JZP-258, Jazz Pharmaceuticals' form of oxybate for narcolepsy, Piper Jaffray analyst David Amsellem reiterates an Overweight rating on the shares with a $213 price target. If JZP-258 were to capture a significant share of the oxybate market, that would translate into not only limited erosion of cash flows from Jazz's oxybate franchise, but also a "significant re-rating of valuation multiples" for Jazz, Amsellem tells investors in a research note. He believes a scenario involving greater than 50% market share for JZP-258 would translate into a value per share of north of $250. Further, the downside risk to the shares in a scenario with limited or no contribution from JZP-258 is "far more limited than the upside potential," contends Amsellem.
10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).
10/15/18
MZHO
10/15/18
NO CHANGE
Target $173
MZHO
Neutral
Jazz Pharmaceuticals price target lowered to $173 from $180 at Mizuho
Mizuho analyst Irina Koffler lowered her price target for Jazz Pharmaceuticals to $173 to reflect reduced estimates for Vyxeos, Erwinaze, and Solriamfetol. The analyst's annual revenue growth estimate for 2018-2027 decreased to 2.6% from 3.5%. He expects Jazz to guide down Erwinaze due to a supply disruption and reiterates a Neutral rating on the shares
11/07/18
RBCM
11/07/18
NO CHANGE
Target $184
RBCM
Outperform
Jazz Pharmaceuticals price target lowered to $184 from $194 at RBC Capital
RBC Capital analyst Randall Stanicky lowered his price target on Jazz Pharmaceuticals to $184 after its Q3 results, saying the company again "missed the mark" on Vyxeos whose launch continues to disappoint. The analyst keeps his Outperform rating on Jazz Pharmaceuticals, citing the "robust" 9% volume growth for Xyrem and its anticipated near-term launches, but believes that unlocking value for investors may take "longer than anticipated".
LNTH Lantheus
$15.70

0.35 (2.28%)

06/18/18
JEFF
06/18/18
NO CHANGE
Target $21
JEFF
Buy
Lantheus position in moly more secure than stock suggests, says Jefferies
A presentation by new molybdenum-99 supplier SHINE Medical Technologies adds more support to Lantheus' (LNTH) position in the market being more secure than the current stock price reflects, Jefferies analyst Raj Denhoy tells investors in a research note. SHINE expects to bring production online in 2021, with Lantheus already contracted to use its molybdenum-99, the analyst adds. He believes the market is "vastly overestimating" the threat from new entrants and "vastly underappreciating" the company's "hold on this market." Denhoy sees little chance of BWX Technologies (BWXT) gaining significant traction given the manufacturing and regulatory challenges in bringing a generator to market. He keeps a Buy rating on Lantheus with a $21 price target.
08/02/18
WELS
08/02/18
NO CHANGE
Target $20
WELS
Outperform
Lantheus price target lowered to $20 from $26 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen lowered his price target for Lantheus to $20 from $26 after the company reported Q2 revenue that missed Street expectations due to a TechneLite supply shortage but modestly beat consensus on adjusted EBITDA. The analyst reiterates an Outperform rating on the shares.
AUPH Aurinia Pharmaceuticals
$5.17

-0.05 (-0.96%)

03/16/18
CANT
03/16/18
NO CHANGE
Target $16
CANT
Overweight
Aurinia price target raised to $16 from $14 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Aurinia Pharmaceuticals to $16 citing a reduction of the company's estimated tax rate to 21% from 35% following its Q4 results. Aurinia remains on track to enroll its Phase 3 Aurora study in Q4 and to initiate studies to advance its pipeline indications for voclosporin in Q2, Piros tells investors in a research note. He reiterates an Overweight rating on the shares.
02/08/18
RBCM
02/08/18
INITIATION
Target $9
RBCM
Outperform
Aurinia Pharmaceuticals initiated with an Outperform at RBC Capital
RBC Capital analyst Douglas Miehm initiated Aurinia Pharmaceuticals with an Outperform rating and a price target of $9. The analyst says the stock represents an "attractive opportunity with upside" based on the Phase 3 study of its lupus nephritis drug voclosporin, which "has potential to become the first FDA-approved treatment for the disease".
08/13/18
HCWC
08/13/18
NO CHANGE
Target $15
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $15 from $12 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Aurinia Pharmaceuticals to $15 after the company announced its pivotal Phase 3 study of voclosporin in lupus nephritis patients is running ahead of schedule. The analyst view the progress as a reflection of the high level of interest and motivation in the trial, by both patients and investigators. He keeps a Buy rating on Aurinia shares.
CRBP Corbus Pharmaceuticals
$5.87

-0.49 (-7.70%)

10/24/18
10/24/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at JMP Securities. 2. Comcast (CMCSA) resumed with a Buy at Deutsche Bank, reinstated with a Buy at Citi, and assumed with a Neutral at Guggenheim. 3. 2U (TWOU) initiated with a Buy at Needham. 4. Corbus Pharmaceuticals (CRBP) initiated with a Buy at B. Riley FBR. 5. Entasis Therapeutics (ETTX) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/18
RAJA
10/03/18
NO CHANGE
RAJA
Outperform
Corbus patent reinforces exclusivity assumptions, says Raymond James
Raymond James analyst Laura Chico noted that Corbus' new method of use patent for the treatment of fibrotic diseases marks the third method patent extending exclusivity to 2034, which she sees as "encouraging on the margin." The patent issuance reinforces her assumption that Corbus can hold exclusivity for lenabasum through 2034, added Chico, who keeps an Outperform rating on the stock.
09/20/18
JMPS
09/20/18
NO CHANGE
Target $27
JMPS
Outperform
Corbus deal for endocannabinoid compounds makes sense, says JMP Securities
JMP Securities analyst Liisa Bayko said she is pleased with Corbus' announcement that it has licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 compounds targeting the endocannabinoid system from Jenrin. While she thinks the deal "makes a lot of strategic sense," Bayko is not yet incorporating the drug candidates into her valuation given the early stage of these assets. Bayko, who said the new assets represent potential upside, keeps an Outperform rating and $27 price target on Corbus shares.
10/24/18
RILY
10/24/18
INITIATION
Target $22
RILY
Buy
Corbus Pharmaceuticals initiated with a Buy at B. Riley FBR
B.Riley FBR analyst George Zavoico started Corbus Pharmaceuticals with a Buy rating and $22 price target.
CNCE Concert Pharmaceuticals
$11.29

-0.505 (-4.28%)

04/10/18
MZHO
04/10/18
NO CHANGE
Target $27
MZHO
Buy
Concert still likely to win IPR challenge against Incyte, says Mizuho
Mizuho analyst Difei Yang does not see a read-through to the final decision from the Patent Trial and Appeal Board's granting Incyte's (INCY) motion for reconsideration as it relates to the Inter Partes Review Petition challenge against Concert Pharmaceuticals (CNCE). The analyst still thinks Concert is likely to win the challenge based on how it has defended its patents historically. The company has an "impressive track record" on intellectual protection front, Yang tells investors in a research note. The analyst reiterates a Buy rating on Concert Pharmaceuticals with a $27 price target. The stock in morning trading is down 5%, or 96c, to $19.08.
09/13/18
JANY
09/13/18
INITIATION
Target $17
JANY
Neutral
Janney Montgomery Scott starts Concert Pharmaceuticals at Neutral
As previously reported, Janney Montgomery Scott initiated Concert Pharmaceuticals (CNCE) with a Neutral rating, with analyst Esther Hong setting a $17 fair value estimate on the shares. She believes AVP-786, which is in Phase 3 in Alzheimer's agitation, has blockbuster potential and she is positive on its lead program, CTP-543 for the treatment of Alopecia Areata. However, Hong remains on the sidelines pending the final decision on CTP-543's patent after Incyte filed an Inter Partes Review petition, noting that the PTAB granted a rehearing request, which it rarely does. She sees the IPR ruling as difficult to predict at this stage.
07/10/18
MZHO
07/10/18
NO CHANGE
Target $27
MZHO
Buy
Concert well positioned into Q4 data catalyst, says Mizuho
Concert Pharmaceuticals is expected to report top-line data from CTP-543 in patients with moderate-to-severe alopecia areata in Q4, Mizuho analyst Difei Yang tells investors in a research note. The analyst expects the readout will be an important catalyst for Concert shares and remains confident in the potential of CTP-543. The company is well positioned relative to most alopecia areata competitors from a timeline perspective, Yang contends. She keeps a Buy rating on Concert Pharmaceuticals with a $27 price target.
09/13/18
JANY
09/13/18
INITIATION
JANY
Neutral
Concert Pharmaceuticals initiated with a Neutral at Janney Montgomery Scott
SGMO Sangamo
$9.50

-1.3 (-12.04%)

11/14/18
JPMS
11/14/18
DOWNGRADE
Target $11
JPMS
Neutral
JPMorgan downgrades Sangamo to Neutral on 'growing skepticism'
JPMorgan analyst Eric Joseph downgraded Sangamo Therapeutics (SGMO) to Neutral from Overweight and lowered his price target for the shares to $11 from $35. Following the company's Q3 results, the analyst has "growing skepticism" about its lead development programs and "their potential for value creation over the foreseeable future." Visibility into the initial efficacy of the SB-525 / Hemophilia A program "continues to elude, now with indefinite timelines," Joseph tells investors in a research note. With relatively slower recruitment to date, the analyst struggles to see how SB-525 closes ground with the two later-stage competitor FVIII gene therapy programs from BioMarin (BMRN) and Spark Therapeutics (ONCE).
11/09/18
GUGG
11/09/18
DOWNGRADE
GUGG
Neutral
Sangamo downgraded to Neutral from Buy at Guggenheim
11/09/18
11/09/18
DOWNGRADE

Neutral
Sangamo downgraded to Neutral after Hemophilia A 'about-face' at Guggenheim
As previously reported, Guggenheim analyst Whitney Ijem downgraded Sangamo to Neutral from Buy after the company reported Q3 earnings and announced that it will not present initial SB-525 in hemophilia A data at ASH in December. The company's "about-face" on the SB-525 data disclosure is concerning and makes Ijem question the timelines around additional updates, she tells investors. While she understand the company's desire to wait for a "complete clinical picture" before announcing data, she worries that it might be a moving target for hemophilia A and potentially other programs, Ijem added. She withdrew her prior $18 price target on Sangamo as she awaits more clarity on what can be expected from the company in 2019.
11/14/18
JPMS
11/14/18
DOWNGRADE
Target $11
JPMS
Neutral
Sangamo downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Eric Joseph downgraded Sangamo Therapeutics to Neutral and lowered his price target for the shares to $11 from $35. The analyst sees a lack of catalysts following last week's Q3 results.
CNST Constellation Pharmaceuticals
$5.83

0.025 (0.43%)

08/13/18
08/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Crinetics (CRNX) was initiated with an Outperform at Leerink, an Overweight at Piper Jaffray, and a Neutral at JPMorgan. 2. Hasbro (HAS) was initiated with an Overweight at Consumer Edge while Mattel (MAT) initiated with an Equal Weight. 3. Allakos (ALLK) initiated with an Outperform at William Blair, a Buy at Jefferies, and a Neutral at Goldman Sachs. 4. Constellation Pharmaceuticals (CNST) was initiated with an Overweight at JPMorgan as well as an Outperform at BMO Capital and Oppenheimer. 5. Rubius Therapeutics (RUBY) initiated with an Outperform at Leerink, an Overweight at JPMorgan and Morgan Stanley, as well as a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/13/18
JPMS
08/13/18
INITIATION
Target $17
JPMS
Overweight
Constellation Pharmaceuticals initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started Constellation Pharmaceuticals with an Overweight rating and $17 price target. The 35% selloff since the initial public offering is overdone and creates an "interesting/compelling entry point ahead of more robust proof-of-concept data" for both CPI-1205/CPI-0610 in mid-2019, Rama tells investors in a research note.
08/13/18
OPCO
08/13/18
INITIATION
Target $21
OPCO
Outperform
Constellation Pharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Constellation Pharmaceuticals with an Outperform rating and $21 price target. The analyst models CPI-1205 to launch in 2023 in prostate cancer and CPI-0610 to launch in 2023 in myelofibrosis. CPI-1205 could result in 2025 product sales of $1.84B, and CPI-0610 could generate 2025 product sales of $249.2M, Rush Cann tells investors i a research note.
08/13/18
BMOC
08/13/18
INITIATION
Target $19
BMOC
Outperform
Constellation Pharmaceuticals initiated with an Outperform at BMO Capital
BMO Capital analyst Do Kim initiated Constellation Pharmaceuticals with an Outperform rating and a price target of $19, saying that while the stock reflects its lead asset CPI-1205, the valuation for its second drug - CPI-0610, a BET inhibitor, for myelofibrosis - is "minimal". The analyst notes that his price target accounts for accounts for risk-adjusted revenues for both programs, but the upside scenario could produce $35 per share price as expects CPI-1205 to show synergistic benefit with Xtandi/Zytiga in castration-resistant prostate cancer and for CPI-0610 to potentially "expand Jakafi's $1B market by improving response rates and increasing treatment duration".
CTLT Catalent
$37.90

-0.34 (-0.89%)

11/07/18
FANA
11/07/18
UPGRADE
Target $43
FANA
Outperform
Catalent upgraded to Outperform from Neutral at First Analysis
First Analysis analyst Steven Schwartz upgraded Catalent to Outperform while lowering his price target for the shares to $43 from $47. The analyst says that while management commentary following a "mixed" fiscal Q1 suggests more risk to near-term achievement of results, he remains confident in the company's medium- and long-term prospects based on a positive view of contract development and manufacturing organization industry dynamics. He upgrades the shares on valuation following yesterday's selloff.
08/28/18
PIPR
08/28/18
NO CHANGE
Target $49
PIPR
Overweight
Catalent can achieve long-term growth and margin targets, says Piper Jaffray
Piper Jaffray analyst Sean Wieland kept his Overweight rating and $49 price target on Catalent after its Q4 earnings beat, saying the company's Biologics segment carried the "bulk of growth" while Softgel "waned". The analyst states that he remains confident in the company's long-term growth and margin targets in spite of the near term headwinds.
10/09/18
UBSW
10/09/18
INITIATION
Target $48
UBSW
Neutral
Catalent initiated with a Neutral at UBS
UBS analyst Daniel Brennan initiated Catalent with a Neutral rating and $48 price target.
10/09/18
UBSW
10/09/18
NO CHANGE
UBSW
UBS initiates coverage of Life Sciences and Diagnostics Tools sector
UBS analyst Daniel Brennan initiated coverage of the Life Sciences and Diagnostics Tools sector. He said demand is accelerating across his universe but valuations are extended. He expects strong fundamentals to continue into 2019 but he said selectivity is the key. In the group, his Buy ratings include Exact Sciences (EXAS), Iqvia (IQV), NanoString (NSTG), Syneos Health (SYNH) and Thermo Fisher (TMO).
URGN UroGen Pharma
$47.81

1.48 (3.19%)

09/13/18
STFL
09/13/18
INITIATION
STFL
Buy
UroGen Pharma initiated with a Buy at Stifel
Stifel analyst Derek Archila initiated UroGen Pharma with a Buy rating and a $70 price target. Archila noted that the company has a late-stage asset that is largely de-risked with an attractive, niche commercial opportunity, and also has an emerging pipeline and validated platform. The analyst added that investors are under appreciating the opportunity for MitoGel in UTUC, and believes the stock has room to run.
04/06/18
OPCO
04/06/18
NO CHANGE
Target $75
OPCO
Outperform
UroGen Pharma price target raised to $75 from $62 at Oppenheimer
Oppenheimer analyst Derek Archila raised his price target on UroGen Pharma to $75 from $62. Archila told investors in a research note that he is increasing his probability of success for MitoGel in upper tract urothelial carcinoma, or UTUC, based on "impressive" interim results from its OLYMPUS Phase 3 study, in which the complete response rate was better than seen in the compassionate use study. Archila reiterated an Outperform rating on UroGen shares.
04/04/18
RAJA
04/04/18
UPGRADE
RAJA
Outperform
UroGen Pharma upgraded to Outperform from Market Perform at Raymond James
11/08/18
JEFF
11/08/18
INITIATION
Target $77
JEFF
Buy
UroGen Pharma assumed with a Buy at Jefferies
Jefferies analyst Chris Howerton assumed coverage of UroGen Pharma with a Buy rating and $77 price target. The company's lead assets have shown "strong" clinical data, and have potential to become standard of care in their respective indications, says the analyst.
ARRY Acquired by PFE
$14.53

-0.18 (-1.22%)

09/17/18
GUGG
09/17/18
INITIATION
GUGG
Guggenheim calls Array, Deciphera, ImmunoGen top biotech picks
Guggenheim initiated coverage of the biotechnology sector, initiating and assuming coverage of 17 biotechnology stocks, and saying it is bullish on the sector longer term and expects continued growth. The firm's coverage focuses on the oncology therapeutic category, with Guggenheim calling Array Biopharma (ARRY), Deciphera Pharmaceuticals (DCPH), and ImmunoGen (IMGN), which all have key catalysts coming in the first half or 2019, its top picks.
09/17/18
GUGG
09/17/18
INITIATION
Target $32
GUGG
Buy
Array BioPharma initiated with a Buy at Guggenheim
Target $32.
08/16/18
JEFF
08/16/18
NO CHANGE
Target $18
JEFF
Buy
After doc survery, Jefferies sees Array melanoma combo estimates as 'achievable'
After conducting a poll of 31 U.S. oncologists on Array Biopharma's recently approved Braftovi/ Mektovi combo treatment for melanoma, Jefferies analyst Eun Yang said the survey leads her to believe her U.S. sales estimate of about $300M in FY2022 seems "quite achievable." Given the poll, she views downside risks for Array shares as limited and maintains a Buy rating and $18 price target on the shares.
08/14/18
PIPR
08/14/18
NO CHANGE
Target $25
PIPR
Overweight
Piper Jaffray 'surprised' Array BioPharma shares are trading lower post-results
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $25 price target for Array BioPharma following the company's Q4 results, telling investors in a research note that he is "surprised" to see shares trading lower today on a "perceived" revenue miss. Tenthoff, who notes that revenues in Q4 were only reimbursement and milestones from partners, says he is a buyer for the Braftovi and Mektovi launch in BRAF-mutant melanoma, which occurred the week of July 2, and projects initial sales of $17.2M in calendar 2018 and $71.5M in calendar 2019.
WST West Pharmaceutical
$106.46

-0.37 (-0.35%)

01/24/18
GSCO
01/24/18
INITIATION
Target $110
GSCO
Neutral
West Pharmaceutical initiated with a Neutral at Goldman Sachs
Goldman analyst Dana Flanders initiated West Pharmaceutical with a Neutral and $110 price target.
04/25/18
BOFA
04/25/18
DOWNGRADE
Target $85
BOFA
Underperform
West Pharmaceutical downgraded to Underperform on reduced growth at BofA/Merrill
As previously reported, BofA/Merrill downgraded West Pharmaceutical to Underperform from Neutral and lowered its price target to $85 from $100. Analyst Derik de Bruin said the company is experiencing ongoing customer inventory issues and mixed endmarkets, resulting a less attractive core growth and margin profile. The analyst views valuation as "more than full" and less deserving of a premium multiple relative to peers.
04/25/18
BOFA
04/25/18
DOWNGRADE
BOFA
Underperform
West Pharmaceutical downgraded to Underperform from Neutral at BofA/Merrill
RUBY Rubius Therapeutics
$18.47

0.71 (4.00%)

08/13/18
JEFF
08/13/18
INITIATION
Target $40
JEFF
Buy
Jefferies starts Rubius Therapeutics with Buy rating, $40 target
Jefferies analyst Michael Yee initiated coverage of Rubius Therapeutics with a Buy rating and $40 price target. The company's platform technology could broadly address a number of blockbuster markets, Yee tells investors in a research note. He sees an "asymmetric risk/reward over time" for the shares.
08/13/18
08/13/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. GOLDMAN SACHS CUTS ALNYLAM TO BUY: Goldman Sachs analyst Terence Flynn downgraded Alnylam (ALNY) to Buy from Conviction Buy. The analyst also lowered his price target for the shares to $155 from $193. Flynn said the lack of cardio data in the approved U.S. label for Onpattro is disappointing and could represent a disadvantage versus Pfizer's (PFE) competitor drug Tafamadis. Piper Jaffray analyst Edward Tenthoff recommended buying shares of Alnylam Pharmaceuticals on weakness following the approval of Onpattro. Morgan Stanley analyst David Lebowitz lowered his price target to $93, Nomura Instinet analyst Christopher Marai lowered his price target to $73, and Stifel analyst Paul Matteis maintained a Buy rating but cut his price target to $123 from $125 and slightly lowered his revenue ramp for the drug based on modestly reduced share in mixed-phenotype haTTR patients and lower share in cardiac-only haTTR patients. B. Riley FBR analyst Madhu Kumar raised his price target to $230. RUBIUS THERAPEUTICS INITIATED AT MULTIPLE FIRMS: Rubius Therapeutics (RUBY) was initiated with an Outperform at Leerink, an Overweight at JPMorgan and Morgan Stanley, as well as a Buy at Jefferies. PIPER JAFFRAY SAYS AMAZON AD BUSINESS GROWING INTO PROFIT DRIVER: Amazon's (AMZN) advertising business "has been quietly growing into a massive driver of current and future profitability," Piper Jaffray analyst Michael Olson told investors in a research note. Applying an advertising comp multiple of 16 times to estimated 2020 Amazon advertising operating income suggests an ad business that should be valued at $150B-$190B, Olson contended. IMPERIAL CAPITAL CUTS NETFLIX PRICE TARGET TO $494: Imperial Capital analyst David Miller lowered his price target for Netflix (NFLX) to $494 after he slightly reduced his global subscriber estimates. The analyst said that in the "interest of being conservative," he decreased his fiscal 2018 global subscriber estimate to 141.2M from 141.4M and fiscal 2019 global subscriber estimate to 164.4M from 166.3M. DISH DOWNGRADED TO SELL AT MOFFETTNATHANSON: MoffettNathanson analyst Craig Moffett downgraded Dish (DISH) to Sell from Neutral with a price target of $29 and noted that while the reported Q2 business conditions in the core satellite TV business were "genuinely better" amid reduced churn and slower subscriber losses, the Spectrum segment -- which holds "all" of the company's equity value -- is worse.
08/13/18
LEER
08/13/18
INITIATION
Target $30
LEER
Outperform
Rubius Therapeutics initiated with an Outperform at Leerink
Leerink analyst Jonathan Chang started Rubius Therapeutics with an Outperform rating and $30 price target as he has a positive long-term view on the stock. While the analyst acknowledges that any valuation method has significant shortcomings at this early stage, he believes that Rubius is "a swing for the fences type of play" with an approach that is uniquely differentiated and could be potentially transformative for the cell therapy field, if successful. Additionally, he views it as well positioned to execute on its strategy with a highly experienced management team and strong financial position.
CARA Cara Therapeutics
$18.12

-0.8 (-4.23%)

09/13/18
JEFF
09/13/18
INITIATION
Target $30
JEFF
Buy
Jefferies starts Cara Therapeutics with Buy rating, $30 price target
Jefferies analyst Matthew Andrews initiated coverage of Cara Therapeutics with a Buy rating and $30 price target. The company's first-in-class Korsuva reduces itch and pain without causing opioid-related side effect, Andrews tells investors in a research note. The analyst expects the two ongoing Phase III trials to generate "similar positive data due to similar protocol and robust prior positive data." He views the top-line Phase III data in mid-2019 as the next key catalyst for Cara shares.
09/13/18
JEFF
09/13/18
INITIATION
Target $30
JEFF
Buy
Cara Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Matthew Andrews started Cara Therapeutics with a Buy rating and $30 price target.
09/21/18
CANT
09/21/18
INITIATION
Target $27
CANT
Overweight
Cara Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Cara Therapeutics with an Overweight rating and $27 price target. The analyst, who started coverage on seven Neuro-Innovator and Platform-Enabled Therapeutic companies, believes that "biotech has entered a golden age of innovation and productivity across many therapeutic areas."
09/21/18
CANT
09/21/18
INITIATION
Target $27
CANT
Overweight
Cara Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald started Cara Therapeutics with an Overweight rating and $27 price target.

TODAY'S FREE FLY STORIES

CMCSA

Comcast

$43.17

0.82 (1.94%)

, AEO

American Eagle

$15.40

0.63 (4.27%)

19:34
08/18/19
08/18
19:34
08/18/19
19:34
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

CMCSA

Comcast

$43.17

0.82 (1.94%)

AEO

American Eagle

$15.40

0.63 (4.27%)

MO

Altria Group

$46.48

1 (2.20%)

CMCSK

Comcast

$0.00

(0.00%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 04

    Sep

  • 25

    Sep

  • 25

    Sep

  • 27

    Oct

  • 13

    Nov

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

19:27
08/18/19
08/18
19:27
08/18/19
19:27
Periodicals
Trump does not want to do business with Huawei, Reuters reports »

President Donald Trump…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XYF

X Financial

$2.61

0.04 (1.56%)

19:25
08/18/19
08/18
19:25
08/18/19
19:25
Earnings
X Financial reports Q2 EPS 31c, consensus 22c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

VJET

Voxeljet

$1.64

-0.05 (-2.96%)

18:44
08/18/19
08/18
18:44
08/18/19
18:44
Recommendations
Voxeljet analyst commentary at Piper Jaffray »

Voxeljet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

$0.00

(0.00%)

, AAPL

Apple

$206.44

4.71 (2.33%)

18:40
08/18/19
08/18
18:40
08/18/19
18:40
Periodicals
Apple CEO warns Trump about China tariffs, Reuters reports »

President Donald Trump…

SSNLF

Samsung

$0.00

(0.00%)

AAPL

Apple

$206.44

4.71 (2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

T

AT&T

$34.98

0.64 (1.86%)

, CMCSA

Comcast

$43.17

0.82 (1.94%)

18:05
08/18/19
08/18
18:05
08/18/19
18:05
On The Fly
Box Office Battle: 'Good Boys' wins weekend with $21M debut »

"Box Office Battle" is…

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$55.72

0.64 (1.16%)

LGF.A

Lionsgate

$11.06

0.02 (0.18%)

LGF.B

Lionsgate

$10.52

0.01 (0.10%)

DIS

Disney

$135.19

1.79 (1.34%)

VIAB

Viacom

$26.02

0.09 (0.35%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 23

    Oct

  • 27

    Oct

SFTBF

SoftBank

$0.00

(0.00%)

, SFTBY

SoftBank

$0.00

(0.00%)

17:59
08/18/19
08/18
17:59
08/18/19
17:59
Periodicals
Softbank plans to lend up to $20B to employees to invest in new fund, WSJ says »

Softbank is planning to…

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

16:50
08/18/19
08/18
16:50
08/18/19
16:50
Periodicals
Trump administration to give Huawei more time to work with U.S. clients,WSJ says »

The Trump administration…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JSAIY

J Sainsbury

$0.00

(0.00%)

16:46
08/18/19
08/18
16:46
08/18/19
16:46
Periodicals
J Sainsbury's not talking to internal candidates for CEO succession,Reuters says »

J Sainsbury's is not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$219.92

4.27 (1.98%)

16:39
08/18/19
08/18
16:39
08/18/19
16:39
Hot Stocks
Tesla relaunching solar-panel business with no-contract rentals »

Tesla is now offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 23

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

16:14
08/18/19
08/18
16:14
08/18/19
16:14
Periodicals
White House says no recession in sight, Reuters reports »

White House officials…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$89.46

0.91 (1.03%)

16:11
08/18/19
08/18
16:11
08/18/19
16:11
Periodicals
Novartis executive sold shares before data manipulation made public,Reuters says »

An unnamed Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

MO

Altria Group

$46.48

1 (2.20%)

16:08
08/18/19
08/18
16:08
08/18/19
16:08
Periodicals
CDC investigating lung illness linked to e-cigarette use, Reuters reports »

The Centers for Disease…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFB

CrossFirst Bancshares

$14.61

(0.00%)

, JFU

9F Inc

$10.09

0.52 (5.43%)

08:48
08/18/19
08/18
08:48
08/18/19
08:48
On The Fly
Opening Day: CrossFirst rises after setting IPO share price lower than expected »

Shares of CrossFirst…

CFB

CrossFirst Bancshares

$14.61

(0.00%)

JFU

9F Inc

$10.09

0.52 (5.43%)

NET

Cloudflare

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

SDC

SmileDirectClub

$0.00

(0.00%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

MSFT

Microsoft

$136.13

2.39 (1.79%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 27

    Oct

CBS

CBS

$43.83

0.5 (1.15%)

, VIA

Viacom

$27.27

-0.4 (-1.45%)

08:03
08/17/19
08/17
08:03
08/17/19
08:03
Periodicals
Viacom-CBS merger got panned by investors, Barron's says »

CBS (CBS) and Viacom…

CBS

CBS

$43.83

0.5 (1.15%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

VIAB

Viacom

$26.02

0.09 (0.35%)

AAPL

Apple

$206.44

4.71 (2.33%)

DIS

Disney

$135.19

1.79 (1.34%)

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

NFLX

Netflix

$302.74

6.81 (2.30%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

  • 27

    Oct

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

07:57
08/17/19
08/17
07:57
08/17/19
07:57
Periodicals
Myriad Genetics stock might have an FDA issue, Barron's says »

Myriad Genetics plunged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CSCO

Cisco

$46.96

0.73 (1.58%)

, NTAP

NetApp

$46.75

0.33 (0.71%)

07:50
08/17/19
08/17
07:50
08/17/19
07:50
Periodicals
Trade war hitting tech stocks, Barron's says »

Cisco (CSCO) plunged 9% a…

CSCO

Cisco

$46.96

0.73 (1.58%)

NTAP

NetApp

$46.75

0.33 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

  • 10

    Oct

  • 13

    Nov

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

, RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

07:47
08/17/19
08/17
07:47
08/17/19
07:47
Periodicals
Investors should not abandon oil, gas stocks, Barron's says »

Energy stocks have rarely…

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

CVX

Chevron

$115.79

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 25

    Sep

TGT

Target

$84.20

1.67 (2.02%)

, WMT

Walmart

$112.99

0.32 (0.28%)

07:40
08/17/19
08/17
07:40
08/17/19
07:40
Periodicals
Grocery Outlet thriving as rivals struggle, Barron's says »

While Dow was down 800…

TGT

Target

$84.20

1.67 (2.02%)

WMT

Walmart

$112.99

0.32 (0.28%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

AEO

American Eagle

$15.40

0.63 (4.27%)

07:33
08/17/19
08/17
07:33
08/17/19
07:33
Periodicals
American Eagle to soar despite trade war, Barron's says »

American Eagle's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 25

    Sep

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

, MTCH

Match Group

$84.53

2.08 (2.52%)

07:27
08/17/19
08/17
07:27
08/17/19
07:27
Periodicals
Dating business might be IAC's best asset, greatest challenge, Barron's says »

IAC (IAC) has rallied 34%…

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

MTCH

Match Group

$84.53

2.08 (2.52%)

IAC

IAC

$249.17

4.21 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 10

    Sep

  • 10

    Oct

AAPL

Apple

$206.44

4.71 (2.33%)

, HAS

Hasbro

$114.29

1.13 (1.00%)

07:13
08/17/19
08/17
07:13
08/17/19
07:13
On The Fly
Week in review How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$206.44

4.71 (2.33%)

HAS

Hasbro

$114.29

1.13 (1.00%)

MAT

Mattel

$10.74

(0.00%)

AGR

Avangrid

$49.29

0.37 (0.76%)

JPM

JPMorgan

$107.73

2.52 (2.40%)

BAC

Bank of America

$27.04

0.79 (3.01%)

C

Citi

$63.46

2.13 (3.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 09

    Sep

  • 02

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 27

    Oct

NCLH

Norwegian Cruise Line

$50.48

1.38 (2.81%)

18:04
08/16/19
08/16
18:04
08/16/19
18:04
Hot Stocks
Norwegian Cruise Line CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$27.12

0.14 (0.52%)

18:01
08/16/19
08/16
18:01
08/16/19
18:01
Hot Stocks
Regional Management CFO buys 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

RTN

Raytheon

$178.10

-0.42 (-0.24%)

17:59
08/16/19
08/16
17:59
08/16/19
17:59
Hot Stocks
Raytheon awarded $199.59M Navy contract for MK 15 CIWS »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.